Chinese Journal of Dermatology ›› 2017, Vol. 50 ›› Issue (2): 145-148.
Previous Articles Next Articles
Jie SUN1,Chun-Yan GONG
Received:2016-05-13
Revised:2016-05-31
Online:2017-02-15
Published:2017-01-24
Contact:
Chun-Yan GONG
E-mail:13057687408@163.com
Jie SUN Chun-Yan GONG. Apremilast: a novel drug for the treatment of plaque psoriasis and psoriatic arthritis[J].Chinese Journal of Dermatology, 2017, 50(2): 145-148.
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| ［1］ | Boehncke WH, Schön MP. Psoriasis［J］. Lancet, 2015, 386（9997）: 983⁃994. DOI: 10.1016/S0140⁃6736（14）61909⁃7. |
| ［2］ | 吴华香, 李军, 郑敏. 银屑病关节炎的临床特征和治疗［J］. 中华皮肤科杂志, 2005, 38（3）: 170⁃171. DOI: 10.3760/j.issn:0412⁃4030.2005.03.013. |
| ［3］ | Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis［J］. Lancet, 2007, 370（9583）: 263⁃271. DOI: 10.1016/S0140⁃6736（07）61128⁃3. |
| ［4］ | Aslam A, Griffiths CE. Drug therapies in dermatology［J］. Clin Med （Lond）, 2014, 14（1）: 47⁃53. DOI: 10.7861/clinmedicine.14⁃1⁃47. |
| ［5］ | Ahmad F, Murata T, Shimizu K, et al. Cyclic nucleotide phospho⁃diesterases: important signaling modulators and therapeutic targets［J］. Oral Dis, 2015, 21（1）: e25⁃50. DOI: 10.1111/odi.12275. |
| ［6］ | Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis［J］. Curr Rheumatol Rep, 2014, 16（9）: 443. DOI: 10.1007/s11926⁃014⁃0443⁃6. |
| ［7］ | Martin TJ. PDE4 inhibitors ⁃ a review of the recent patent literature［J］. IDrugs, 2001, 4（3）: 312⁃338. |
| ［8］ | Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase⁃4 inhibitor, demonstrates anti⁃inflammatory activity in vitro and in a model of psoriasis［J］. Br J Pharmacol, 2010, 159（4）: 842⁃855. DOI: 10.1111/j.1476⁃5381.2009.00559.x. |
| ［9］ | Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase Ⅲ, randomized, placebo⁃controlled trial （PALACE 1）［J］. J Immunol Res, 2015, 2015: 906349. DOI: 10.1155/2015/906349. |
| ［10］ | Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity［J］. Cell Signal, 2014, 26（9）: 2016⁃2029. DOI: 10.1016/j.cellsig.2014. 05.014. |
| ［11］ | Otezla （apremilast） prescribing information［DB/OL］. December 2014. http://www.otezla.com/otezla⁃prescribing⁃information.pdf. |
| ［12］ | Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial［J］. Lancet, 2012, 380（9843）: 738⁃746. DOI: 10.1016/S0140⁃6736（12）60642⁃4. |
| ［13］ | Strand V, Fiorentino D, Hu C, et al. Improvements in patient⁃reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase Ⅱb randomized, controlled study［J］. Health Qual Life Outcomes, 2013, 11： 82. DOI: 10.1186/1477⁃7525⁃11⁃82. |
| ［14］ | Papp KA, Kaufmann R, Thaçi D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase Ⅱ, multicenter, randomized, double⁃blind, placebo⁃controlled, parallel⁃group, dose⁃comparison study［J］. J Eur Acad Dermatol Venereol, 2013, 27（3）: e376⁃383. DOI: 10.1111/j.1468⁃3083.2012.04716.x. |
| ［15］ | Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase Ⅲ, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015, 73（1）: 37⁃49. DOI: 10.1016/j.jaad.2015.03.049. |
| ［16］ | Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phase Ⅲ, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015, 173（6）: 1387⁃1399. DOI: 10.1111/bjd.14164. |
| ［17］ | Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult⁃to⁃treat nail and scalp psoriasis: results of 2 phase Ⅲ randomized, controlled trials （ESTEEM 1 and ESTEEM 2）［J］. J Am Acad Dermatol, 2016, 74（1）: 134⁃142. DOI: 10.1016/j.jaad.2015.09. 001. |
| ［18］ | Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double⁃blind, placebo⁃controlled study［J］. Arthritis Rheum, 2012, 64（10）: 3156⁃3167. DOI: 10.1002/art.34627. |
| ［19］ | Strand V, Schett G, Hu C, et al. Patient⁃reported Health⁃related Quality of Life with apremilast for psoriatic arthritis: a phase Ⅱ, randomized, controlled study［J］. J Rheumatol, 2013, 40（7）: 1158⁃1165. DOI: 10.3899/jrheum.121200. |
| ［20］ | Kavanaugh A, Mease PJ, Gomez⁃Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo⁃controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor［J］. Ann Rheum Dis, 2014, 73（6）: 1020⁃1026. DOI: 10.1136/annrheumdis⁃2013⁃205056. |
| ［21］ | Kavanaugh A, Mease PJ, Gomez⁃Reino JJ, et al. Longterm （52⁃week） results of a phase Ⅲ randomized, controlled trial of apremilast in patients with psoriatic arthritis［J］. J Rheumatol, 2015, 42（3）: 479⁃488. DOI: 10.3899/jrheum.140647. |
| ［22］ | Kavanaugh A, Adebajo A, Gladman D, et al. Long⁃term （104⁃week） efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Results from a phase Ⅲ, randomized, controlled trial and open⁃label extension （PALACE 1）［C/OL］//70th Annual Meeting of the Canadian Rheumatology Association, Quebec City, QC Canada, 2015. Canada: J Rheumatol, 2015, 42（7）. |
| ［23］ | Kavanaugh A, Gladman DD, Gomez⁃Reino JJ, et al. Long⁃term （156⁃week） efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: Results from a phase Ⅲ, randomized, controlled trial and open⁃label extension （PALACE 1）［J］. Arthritis Rheumatol, 2015, 72（5 Suppl 1）: AB227. |
| ［24］ | Cutolo M, Myerson GE, Fleischmann RM, et al. Long⁃term （52⁃week） results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis （PALACE 2）［C/OL］//ACR/ARHP Annual Meeting, San Diego, 2013. |
| ［25］ | Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase Ⅲ, randomised, controlled trial （PALACE 3）［J］. Ann Rheum Dis, 2016, 75（6）: 1065⁃1073. DOI: 10.1136/annrheumdis⁃2015⁃207963. |
| ［26］ | Edwards CJ, Wells AF, Adebajo AO, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long⁃term （52⁃Week） improvements in enthesitis or dactylitis in patients with psoriatic arthritis: results from the PALACE 4 phase 3, randomized, controlled trial. Annual European Congress of Rheumatology （EULAR）, Paris, 2014［J］. Paris: Ann Rheum Dis, 2014, 73: 735. DOI: 10.1136/annrheumdis⁃2014⁃eular.1574. |
| ［27］ | Mease P, Gladman D, Kavanaugh A, et al. Change in weight from baseline during the Palace Clinical Trial Program with apremilast, an oral phosphodiesterase 4 inhibitor: pooled results from 3 phase 3, randomized, controlled trials［J］. Ann Rheum Dis, 2014, 73（Suppl 2）: 1055. DOI: 10.1136/annrheumdis⁃2014⁃eular.2391. |
| ［28］ | Menter A, Paul C, Stevens RM, et al. Psychiatric disorders and depression incidence with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials［C/OL］//23rd Congress of the European Academy of Dermatology and Venereology, Amsterdam, 2014. |
| ［29］ | Papp KA, Reich K, Sobell JM, et al. Two⁃year safety of apremi⁃last, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: results from a phase 3, randomized, controlled trial （ESTEEM 1）［J］. J Am Acad Dermatol, 2015, 72（5 Suppl 1）: AB256. |
| ［30］ | Kurd SK, Troxel AB, Crits⁃Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population⁃based cohort study［J］. Arch Dermatol, 2010, 146（8）: 891⁃895. DOI: 10.1001/archdermatol.2010.186. |
| ［31］ | Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population: national health and nutrition examination survey 2009⁃2012［J］. JAMA Dermatol, 2016, 152（1）: 73⁃79. DOI: 10.1001/jamadermatol.2015.3605. |
| ［32］ | Feldam SR, Tencer T, Clancy Z, et al. Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis［C/OL］//73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA, 2015. |
| ［33］ | Liu Y, Zhou S, Nissel J, et al. The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis［J］. Clin Pharmacol Drug Dev, 2014, 3（6）: 456⁃465. DOI: 10.1002/cpdd.109. |
| ［34］ | Danesh MJ, Beroukhim K, Nguyen C, et al. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis［J/OL］. Dermatol Online J, 2015, 21（6）［2016⁃03⁃20］. http://escholarship.org/uc/item/5gf406zs. |
| No related articles found! |
|
